

Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

NCT02958462

Status	RECRUITING
Phase	Not Applicable
Sponsor	Mayo Clinic
Enrollment	2,000 participants

Key Eligibility Criteria

Inclusion (8)

- Patients with idiopathic cytopenias of unclear significance (ICUS)
 - Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential [CHIP]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)
 - Patients with clonal cytopenias of undetermined significance (CCUS)
 - Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders
 - Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.
- ... and 3 more (see full listing online)

Exclusion (1)

- Patients under 18 years of age

Locations (3 total)

Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Mayo Clinic in Florida, Jacksonville, Florida, United States
Mayo Clinic in Rochester, Rochester, Minnesota, United States